Niki BioSolutions, Inc. · NASDAQ:NIKI
Niki BioSolutions — Aptorum Group — Investor Presentation (April 2019)
13 slides from Niki BioSolutions's investor presentation, Apr 24, 2019
Slide 1: Aptorum SmartPharma
\. SMARTPHAR APTORUM q\ iS, NASDAQ: APM aptorumgroup.com
Slide 2: Nasdaq Listed
NasdaqListed a cisco 7 9 = 52 ja 9 = S84 +2.08% 431,33 -0.19% -0,08 +0.78% 40.50 +206ut3L53 thBlibetwe oc sea Som Sar SL,S82.24 SLSS224 PRICE S4é.11 SM. PRE $8497 / “= $8497 PRICE SLSS224/ “ar $1,852.24 PRICE $85.62 / On 18th December 2018, Aptorum Group Limited listed on the NASDAQ (ticker symbol:
Slide 3: ACT - Accelerating the Commercialisation of Therapeutics
ACT- Accelerating the Commercialisation of Therapeutics (ae 69% 60%" 36%! fy success success success DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 Traditionally, drug discovery and development (“3D”) is a time-consuming, costly and high-risk business TIME FAILURE RATE 86.2% nearly 86.2% of drug cand
Slide 4: ACT - Accelerating the Commercialisation of Therapeutics
ACT- Accelerating the Commercialisation of Theapetic > COMPUTATIONAL ALGORITHMS AND BIG DATA Protein docking, genetic simulation, immunology, genomics, bioimaging, animal studies, proteomics COMPUTATIONAL ALGORITHMS & BIG DATA e REPURPOSE Potentially skip preclinical and Phase | by using existing da
Slide 5: Traditional 3D & ACT3D
UV ti ititCPi CS SS GStwttitiitritrrnr: TRADITIONAL 3D & ACT3D Traditional 3D a 5-6.5 years Drug Discovery: 1-1.5 year including wet RED CE 10-17 years* St lab validation Drug Discovery: varies, 3-10 years? a Preclinical Development: may not needed Time Preclinical Development: 9 months to one . . a
Slide 6: Life Examples: Neuroblastoma
LIFE EXAMPLES: Neurob aston a sn TARGET A TARGET B TARGET C Lump inthe abdomen Lump inthe chest 14 drugs identified 20 drugs identified 12 drugs identified Wet Lab Validation 2019 Phase 3 Trial Done 2021 Regulatory Approval 2024 Commercialisation 2025 Total 6 years” = Timeline is for illustrative pu
Slide 7: ACT team and advisors
£ g Dr.Justin Or. Nishant wu AGRAWAL eheiot Actor lniotsavieor a «& Dr.Philip Dr. Vincent. cHIU MoK Clniot Advisor cinco Aavieor Dr.Monique Ms. Margaret Ue BURKE Ms. Flora Mr.Johnny HO WONG Potenthgent ‘Patent Speciast & swanteHanma ACT- Accelerating the Commercialisation of Therapeutics 2 Dr. Henry
Slide 8: Potential of ACT
ACT- Accelerating the Commercialisation of thet? === Potential of ACT ACT THERAPEUTIC PORTFOLIO VALUATION VERSUS PROJECTED CLINICAL ASSETS: Commercialisation + Out-Licensing Monetization Strategies Orphan Diseases 7000 mmm Est. # Cumulative New Candidates Emerging From Validation; Ins Est. # mm Cumu
Slide 9: Security Token: Smart Pharma Token (SMPT)
Token Symbol Token Type Total Token Supply Tokens available for Public Retention by Issuer's staff, partners and ecosystem Retention by Issuer Secondary Market Issuer Technology Partner GJ swantewanwa SMPT ERC-1404 security compliant tokens with ERC- 20 and ERC-233 compliance on the Ethereum blockch
Slide 10: Security Token: Smart Pharma Token (SMPT)
SECURITY TOKEN: SMART PHARMA TOKEN (SMPT) ABOUT SMPT (i) Backed by assets of SPLP issuer, including intellectual property portfolio of all repurposed drugs discovered under the Smart-ACT™ platform and related allocated cashflows (e.g. royalties from commercialised sales, annual fixed licensing fees,
Slide 11: Security Token: Smart Pharma Token (SMPT)
SECURITY TOKEN: SMART PHARMA TOKEN (SMPT) PROJECTED SMPT INTRINSIC VALUE (US$) PER TOKEN! SMPT Token is backed by asset IME Fst. # Cumulative New Candidates Emerging From Validation; rhs pipeline of Smart-ACT™ mM £1. Cumulative Clinical Assets in Pipeline; hs <@= Mid-point sMPr token value; ths TOKE
Slide 12: Disclaimer
qu ORG AL NOVICES EE Nothingin this presentation shall be deemed to constitute a prospectus of any sort, a solicitation for investment or investment advice nor does itin any way pertain to an offering or a solicitation of an offer to buy any securities in any jurisdiction, This presentation contains
Slide 13: Contact Us
SMARTPHARMA APTORUM § SMARTPHARMA SMART PHARMA E Ww info@smtph.com www.smtph.com APTORUM GROUP T E A Ww +852 2117 6611 info@aptorumgroup.com 17/F, Guangdong Investment Tower, 148 Connaught Road Central, Hong Kong www.aptorumgroup.com CONTACT US === STAY IN H @sz+6€A t.me/Smtpharma twitter.com/smtpha